BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focusing on genetic diseases, has announced the approval of equity grants for 17 new employees. The grants, approved by the compensation committee on August 6, 2024, consist of restricted stock units totaling 71,859 shares of the company's common stock. The vesting schedule includes one-fourth of the shares vesting on August 16, 2025, followed by quarterly vesting of one-twelfth of the remaining shares, subject to continued employment. These grants were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), as inducements for the new employees joining the company.
BridgeBio Pharma (Nasdaq: BBIO), un'azienda biofarmaceutica in fase commerciale che si concentra sulle malattie genetiche, ha annunciato l'approvazione di concessioni azionarie per 17 nuovi dipendenti. Le concessioni, approvate dal comitato retribuzioni il 6 agosto 2024, consistono in unità azionarie vincolate per un totale di 71.859 azioni ordinarie dell'azienda. Il programma di maturazione prevede che un quarto delle azioni maturi il 16 agosto 2025, seguito dalla maturazione trimestrale di un dodicesimo delle azioni rimanenti, a condizione di continuare a lavorare. Queste concessioni sono state effettuate nell'ambito del Piano di Incentivazione Azionaria 2019 Modificato e Rifatto di BridgeBio, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4), come incentivo per i nuovi dipendenti che entrano a far parte dell'azienda.
BridgeBio Pharma (Nasdaq: BBIO), una compañía biofarmacéutica en etapa comercial que se enfoca en enfermedades genéticas, ha anunciado la aprobación de grantes de acciones para 17 nuevos empleados. Las grantes, aprobadas por el comité de compensación el 6 de agosto de 2024, consisten en unidades de acciones restringidas que totalizan 71,859 acciones ordinarias de la compañía. El cronograma de adquisición incluye que una cuarta parte de las acciones se adquiera el 16 de agosto de 2025, seguido por adquisiciones trimestrales de un duodécimo de las acciones restantes, sujeto a la continuidad del empleo. Estas concesiones se realizaron bajo el Plan de Incentivos de Acciones 2019 Modificado y Reestablecido de BridgeBio, de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq, como incentivos para los nuevos empleados que se unen a la compañía.
BridgeBio Pharma (Nasdaq: BBIO)는 유전 질환에 중점을 둔 상업 단계의 생명 공학 회사로, 17명의 신규 직원에 대한 주식 제공 승인을 발표했습니다. 이 주식 제공은 2024년 8월 6일 보상 위원회에서 승인되었으며, 총 71,859주의 제한된 주식 단위로 구성되어 있습니다. 취득 일정에는 2025년 8월 16일에 4분의 1이 취득되며, 이후 나머지 주식의 12분의 1이 매 분기마다 취득되는 조건이 포함되어 있습니다. 이러한 제공은 BridgeBio의 개정 및 재설정된 2019 유도 주식 계획에 따라 이루어졌으며, 새로운 직원들이 회사에 합류하는 것을 유도하기 위해 Nasdaq 상장 규칙 5635(c)(4)에 따라 진행되었습니다.
BridgeBio Pharma (Nasdaq: BBIO), une société biopharmaceutique en phase commerciale axée sur les maladies génétiques, a annoncé l'approbation de attributions d'actions pour 17 nouveaux employés. Les attributions, approuvées par le comité de rémunération le 6 août 2024, consistent en unités d'actions restreintes totalisant 71 859 actions ordinaires de l'entreprise. Le calendrier d'acquisition comprend un quart des actions qui sera acquis le 16 août 2025, suivi d'un acquisition trimestrielle d'un douzième des actions restantes, sous réserve de l'emploi continu. Ces attributions ont été réalisées dans le cadre du Plan de Induction en Actions Modifié et Rénové 2019 de BridgeBio, conformément à la règle de cotation Nasdaq 5635(c)(4), en tant qu'incitatifs pour les nouveaux employés rejoignant la société.
BridgeBio Pharma (Nasdaq: BBIO), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf genetische Erkrankungen spezialisiert hat, hat die Genehmigung von Aktienoptionen für 17 neue Mitarbeiter bekannt gegeben. Die Optionen, die am 6. August 2024 vom Vergütungsausschuss genehmigt wurden, bestehen aus eingeschränkten Aktieneinheiten mit insgesamt 71.859 Aktien des Unternehmens. Der Vesting-Plan sieht vor, dass ein Viertel der Aktien am 16. August 2025 fällig wird, gefolgt von einer vierteljährlichen Fälligkeit von ein Zwölftel der verbleibenden Aktien, unter der Voraussetzung, dass die Mitarbeiter weiterhin beschäftigt bleiben. Diese Optionen wurden im Rahmen des Änderten und Neufassenden Anreiz-Aktienplans 2019 von BridgeBio gewährt, gemäß der Nasdaq-Listing-Regel 5635(c)(4), als Anreiz für die neuen Mitarbeiter, die dem Unternehmen beitreten.
- Attraction of new talent with 17 new employees joining the company
- Implementation of employee retention strategy through equity grants
- Potential dilution of existing shareholders' stock due to the issuance of 71,859 new shares
PALO ALTO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on August 6, 2024, the compensation committee of BridgeBio’s board of directors approved equity grants to 17 new employees in restricted stock units for an aggregate of 71,859 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on August 16, 2025, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”).
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.
BridgeBio Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220
FAQ
How many new employees received equity grants from BridgeBio Pharma (BBIO) on August 6, 2024?
What is the total number of restricted stock units granted by BridgeBio Pharma (BBIO) to new employees?
When will the first portion of the restricted stock units granted by BridgeBio Pharma (BBIO) vest?
Under which plan were the equity grants made by BridgeBio Pharma (BBIO)?
